IONS News

Ionis to present at upcoming investor conferences

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

Ionis reports third quarter 2025 financial results and highlights progress on key programs

Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions

Ionis to hold third quarter 2025 financial results webcast

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases